Every 8-K that ANEBULO PHARMAC INC (ANEB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANEB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANEB filings page.
Anebulo Pharmaceuticals plans to voluntarily delist its common stock from Nasdaq and deregister with the SEC, ending its regular public reporting. The company expects to file Form 25 around February 17, 2026, with delisting effective February 27, 2026, followed by a Form 15 to suspend reporting obligations, based on having fewer than 300 holders of record. The board cites the high costs and management burden of being a listed reporting company. After delisting, trading would occur only through privately negotiated transactions and potentially over-the-counter markets.
For the quarter ended December 31, 2025, total operating expenses were $2.6 million, flat year over year. Net loss was $2.0 million, or $(0.05) per share, versus a $2.5 million loss, or $(0.09) per share, a year earlier. Cash and cash equivalents were $9.0 million, and the company has access to an additional $3.0 million via a loan agreement.
Anebulo Pharmaceuticals, Inc. announced that its board has approved the voluntary delisting of its common stock from The Nasdaq Capital Market and the voluntary deregistration of its common stock with the SEC to end its Exchange Act reporting obligations.
The company notified Nasdaq of its plan and intends to file a Form 25 on or about February 17, 2026, with the delisting expected to be effective on February 27, 2026. Anebulo also plans to file a Form 15 on or about February 27, 2026, which will immediately suspend its duty to file periodic SEC reports. The board cited the significant costs and management burden of remaining a Nasdaq-listed, SEC-reporting company as the reason for this decision, and noted that any future trading in the stock would likely occur in privately negotiated transactions or potentially on the over-the-counter market.
Anebulo Pharmaceuticals completed its previously announced share tender offer, repurchasing 300,000 shares of common stock at $3.50 per share for an aggregate cost of approximately $1.05 million, excluding fees and expenses.
The offer was oversubscribed, with 4,907,881 shares properly tendered and not withdrawn. After applying a final proration factor of 3.47392%, Anebulo accepted 300,000 shares, including 134,306 odd-lot shares accepted in full. The repurchased shares represent about 0.73% of shares outstanding as of January 26, 2026, with cash payment to sellers to be made promptly.
Anebulo Pharmaceuticals reported preliminary results of its cash tender offer to repurchase up to 300,000 shares of its common stock at $3.50 per share. The offer expired on January 26, 2026.
Based on the depositary’s initial count, about 4,897,188 shares were properly tendered and not withdrawn, meaning the offer was oversubscribed. The company currently expects to buy the full 300,000 shares for an estimated total cost of about $1.05 million, excluding related fees and expenses.
Because far more shares were tendered than the company offered to purchase, Anebulo expects to accept shares on a pro rata basis, except that “odd lot” holders will be accepted in full. The preliminary proration factor is approximately 3.51542%, and the shares expected to be purchased represent roughly 0.73% of shares outstanding as of January 26, 2026. Final results will be announced after the guaranteed delivery period and confirmation by the depositary.
Anebulo Pharmaceuticals plans to start a cash tender offer on December 22, 2025 to buy up to 300,000 shares of its common stock at $3.50 per share, for a maximum of $1,050,000. This voluntary self-tender is part of a strategy to complete a “go private” transaction by keeping the number of stockholders below 300.
The board has decided to abandon a previously proposed reverse stock split, which would have paid $3.50 per fractional share, after activity by some holders using multiple small accounts significantly increased the expected cost. Instead, the company will proceed with the tender offer, while reserving the right to consider a reverse split or other alternatives in the future. The tender offer has not yet commenced and will proceed only under the terms described in formal offer documents that will be sent to stockholders and filed with the SEC.
Anebulo Pharmaceuticals, Inc. furnished an update on its business and recent financial performance. On November 13, 2025, the company issued a press release detailing its financial results for the quarter ended September 30, 2025 and providing a broader business update. That press release is attached as Exhibit 99.1 to this report and is being treated as furnished rather than filed, which limits its use for certain legal purposes under securities laws.
Anebulo Pharmaceuticals, Inc. furnished a current report describing the release of its financial results for the quarter and fiscal year ended June 30, 2025 and a related business update. The company issued a press release on September 29, 2025 covering these results, which is included as Exhibit 99.1. The report states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will only be incorporated into other securities filings if specifically referenced.